A second umbrella-phase 2 trial, BATTLE-2[19], has recently been launched to investigate predictive biomarkers for double drug combinations targeting EGFR, MEK and PI3K/AKT in refractory NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.